Assessing risk of unintended antigen occurrence in food: A case instance for maize-expressed LT-B

Human and Ecological Risk Assessment

Volumn 12, Issue 5, 2006, Pages 856-870

  Wolt, Jeffrey D ^a   Wang, Kan ^a   Peterson, Robert K D ^b  

^a IOWA STATE UNIVERSITY   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

Author keywords

Confinement; Enterotoxin subunit B; Escherichia coli; Transgenic; Vaccine

Indexed keywords

ESCHERICHIA COLI; MAMMALIA; ZEA MAYS;

EID: 33748486744     PISSN: 10807039     EISSN: 15497860     Source Type: Journal    
DOI: 10.1080/10807030600826805     Document Type: Article

References (39)

1. AgMRC (Agricultural Marketing Resource Center). 2003. The U.S. Corn Masa Industry: Structure and Implications for the Great Plains Region. Prepared for AgMARC by Sparks Companies, Inc., Department of Agricultural Economics, Kansas State University, Manhattan, KS, USA
2. Bannon G, Fu T-J, Kimber I, et al. 2003. Protein digestibility and relevance to allergenicity. Environ Health Persp 111:1122-4
3. Bucchini L and Goldman LR. 2002. Starlink maize: A risk analysis. Environ Health Persp 110:5-13
4. Cheng E, Ćardenas-Freytag L, and Clements JD. 2000. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT). Vaccine 18:38-49
5. Chikwamba RK, McMurray J, Shou H, et al. 2002. Expression of a synthetic E. coli heat-labile enterotoxin B sub-unit (LT-B) in maize. Molec Breed 10:253-65
6. Chikwamba RK, Scott MP, Meja LB, et al. 2003. Localization of a bacterial protein in starch granules of transgenic maize kernels. Proc Nat Acad Sci USA 100:11127-32
7. Christensen P, Misra MK, Rai S, et al. 2005. Confined Production Processes for Non-Food Corn. Biosafety Institute for Genetically Modified Agricultural Products, Iowa State University, Ames, IA, USA
8. Dickinson BL and Clements JD. 1996. Use of Escherichia coli heat-labile enterotoxin as an oral adjuvant. In: Kiyono H, Ogra PL, and McGhee JR (eds), Mucosal Vaccines. pp 73-87. Academic Press, Inc., San Diego, CA, USA
9. EC (European Commission). 2000. Report of the Scientific Steering Committee's Working Group on Harmonisation of Risk Assessment Procedures in the Scientific Committees advising the European Commission in the area of human and environmental health-26-27 October 2000. European Commission Directorate-General Health & Consumer Protection, Brussels, Belgium
10. EFSA (European Food Safety Authority). 2004. Draft Guidance Document for the Risk Assessment of Genetically Modified Plants and Derived Food and Feed, April 2004. European Food Safety Authority, Brussels, Belgium
11. FAO (Food and Agriculture Organization). 2001. Joint FAO/WHO Expert Consultation on Allergenicity of Foods Derived from Biotechnology, 2001. Evaluation of allergenicity of genetically modified foods. 22-25 Jan 2001. FAO/WHO, Rome, Italy
12. Gendel S. 1998. The use of amino acid sequence alignments to assess potential allergenicity of proteins used in genetically modified foods. Adv Food Nutr Res 42:45-62
13. Guidry JJ, Cardenas L, Cheng E, et al. 1997. Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of E. coli heat labile enterotoxin. Infect Immun 65:4943-50
14. HNRC (Human Nutrition Research Center). 1998. Continuing Survey of Food Intakes by Individuals (CSFII) 1994-96, 1998 Data File. NTIS PB2000-500027. USDA Agricultural Research Service, Beltsville, Maryland, USA
15. Howard JA and Donnelly KC. 2004. A quantitative safety assessment model for transgenic protein products produced in agricultural crops. J Agric Environ Ethics 17:545-58
16. IHC (International Conference on Harmonisation). 1997. Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, ICH Harmonised Tripartite Guideline S6, 16 July 1997. ICH Secretariat, Geneva, Switzerland
17. Kodell RL and Gaylor DW. 1999. Combining uncertainty factors in deriving human exposure levels of noncarcinogenic toxicants. Annals NY Acad Sci 895:188-95
18. Lamphear BJ, Streatfield SJ, Jilka JM, et al. 2002. Delivery of subunit vaccines in maize seed. J Controlled Release 85:169-80
19. Ma JK-C, Drake PMW, and Christou P. 2003. The production of recombinant pharmaceutical protein in plants. Nature Reviews Genetics 4:794-805
20. Macilwain C. 2005. US launches probe into sales of unapproved transgenic corn. Nature 434:423
21. Millar GG, Hirst TR, and Snider DP. 2001. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infection Immun 69:3476-82
22. NASS (National Agricultural Statistics Service). 2005. Crop Production Acreage Supplement. 30 June 2005. Available at http://usda.mannlib.cornell.edu/ reports/nassr/field/pcp-bba/acrg0605.txt
23. Petersen BJ, Rachman, NJ, and Watters JL. 2001. Estimated Potential Dietary Intake of Cry9c Protein Based on Measurements of Cry9c In Processed Foods Made from 100% Starlink™ Corn. Available at http://www.epa.gov/ pesticides/biopesticides/pips/old/stlink/starlink_ 01-01_86-5_report_final.pdf
24. Peterson RKD and Arntzen CJ. 2004. On risk and plant-based biopharmaceuticals. Trends Biotechnol 22:64-6
25. Samyn-Petit B, Gruber V, Flahaut C, et al. 2001. N-glycosylation potential of maize: The human lactoferrin used as a model. Glycoconjugate J 18:519-27
26. SOT (Society of Toxicology). 2002. Proceedings of the Workshop on Non-clinical Safety Evaluation of Preventive Vaccines: Recent Advances and Regulatory Considerations. Available at http://www.toxicology.org/ai/meet/cct- vaccines.asp
27. Streatfield SJ, Mayor JM, Barker DK, et al. 2002. Development of an edible subunit vaccine in corn against enterogenic strains of Eschericia coli. In Vitro Cell Dev-Plant 38:11-17
28. Tacket CO, Mason HS, Losonsky G, et al. 1998. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nature Medicine 4:607-9
29. Takeda Y, Honda T, Taga S, et al. 1981. In vitro formation of hybrid toxins between subunits of Escherichia coli heat-labile enterotoxin and those of cholera enterotoxin. Infection Immun 34:341-6
30. USDA (United States Department of Agriculture). 2002. USDA investigates biotech company for possible permit violations. Available at http://www.aphis.usda.gov/lpa/news/2002/11/prodigene.html
31. USEPA (United States Environmental Protection Agency). 1998. Bacillus thuringiensis Sub-species tolworthi Cry9C Protein and the Genetic Material Necessary for its Production in Corn; Exemption from the Requirement of a Tolerance Related Material. Federal Register 63:28258-61
32. USEPA(US Environmental Protection Agency). 2001a. Pesticide Fact Sheet: Bacillus thuringiensis subspecies Cry1F Protein and the Genetic Material Necessary for Its Production (Plasmid Insert PHI 8999) in Corn. EPA Office of Prevention, Pesticides, and Toxic Substances, Washington, DC, USA
33. USEPA (US Environmental Protection Agency). 2001b. Biopesticides Registration Action Document-Bacillus thuringiensis Plant-Incorporated Protectants. EPA Office of Prevention, Pesticides, and Toxic Substances, Washington, DC, USA
34. USEPA (US Environmental Protection Agency). 2003. CSFII Analysis of Food Intake Distributions, EPA/600/R-03/029. EPA Risk Assessment Forum, Washington, DC, USA
35. USFDA (US Food and Drug Administration). 2003. Guidance for Industry: Drugs, Biologics, and Medical Devices Derived from Bioengineered Plants for Use in Humans and Animals, Draft Guidance. FDA Center for Biologics Evaluation and Research, Washington, DC, USA
36. Wang K, Chikwamba R, and Cunnick J. 2004. Plant-based oral vaccines. Ch. 18 In: Kaufmann SHE (ed.), Novel Vaccination Strategies. Wiley-VCH Verlag, Weinheim, Germany
37. Williams NA. 2000. Immune modulation by the cholera-like enterotoxin B-subunits: From adjuvant to immunotherapeutic. Intl J Med Microbiol 290:447-53
38. Wolt JD and Peterson RKD. 2000. Agricultural biotechnology and societal decision-making: The role of risk analysis. AgBioForum 3:291-8
39. Wolt JD, Shyy Y-Y, Christensen P, et al. 2004. Quantitative exposure assessment for confinement of maize biogenic systems. Environ Biosafety Res 3:183-96